Spironolactone
Product Images NDC 70934-256

4 FDA label images from Denton Pharma, Inc. Dba Northwind Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 70934-256). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (70934 256 30 Rev A 02 19)

Label (70934 256 30 Rev A 02 19)
Spironolactone Tablets USP 25 mg carton label from Denton Pharma, Inc. DBA Northwind Pharmaceuticals. Contains 30 tablets. The label includes storage instructions to keep in original container, protect from light, and store at 20°-25°C. The package is marked Rx only, with dosage instructions referring to the package insert. Multiple smaller labels for individual 30-tablet bottles are also shown.*
FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)
A Kaplan-Meier survival plot comparing Spironolactone and placebo groups over time in months. The y-axis represents probability from 0 to 1, and the x-axis shows months up to 48. The graph includes population sizes for each group and a log-rank p-value indicating statistical significance.*
FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)
A forest plot chart showing hazard ratios (HR) and 95% confidence intervals (CI) across various subgroups for patients taking Spironolactone versus placebo. Subgroups include age, sex, race, LVEF%, heart failure type, NYHA class, diabetes status, serum creatinine levels, creatinine clearance, potassium levels, Digoxin, ACE inhibitors, and beta blocker use. The horizontal axis ranges from 0.2 to 1.4 with annotations indicating "Spironolactone better" on the left and "Placebo better" on the right.*
FDA Label Image

Chemical Structure (Spironolactone Structure Image)

Chemical Structure (Spironolactone Structure Image)
Chemical structure diagram of Spironolactone showing its molecular components including rings and functional groups such as lactone and thioacetate substituents.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.